Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc (PTPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 393
  • Shares Outstanding, K 31,160
  • Annual Sales, $ 5,110 K
  • Annual Income, $ -14,320 K
  • EBIT $ -5 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.68
  • Price/Sales 0.07
  • Price/Cash Flow N/A
  • Price/Book 0.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -39.07
  • Most Recent Earnings $-0.03 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0102 +29.41%
on 12/02/25
0.0181 -27.07%
on 11/13/25
-0.0049 (-27.07%)
since 11/12/25
3-Month
0.0102 +29.41%
on 12/02/25
0.0286 -53.85%
on 09/15/25
-0.0148 (-52.86%)
since 09/12/25
52-Week
0.0102 +29.41%
on 12/02/25
16.2500 -99.92%
on 02/14/25
-8.7418 (-99.85%)
since 12/12/24

Most Recent Stories

More News
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches

Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (MAHA)...

PTPI : 0.0127 (+0.79%)
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

Company's AI and Big Data technology positioned to drive strong industry collaboration

PTPI : 0.0127 (+0.79%)
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter...

PTPI : 0.0127 (+0.79%)
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0127 (+0.79%)
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter...

PTPI : 0.0127 (+0.79%)
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0127 (+0.79%)
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access

PTPI : 0.0127 (+0.79%)
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0127 (+0.79%)
The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company’s Board of Directors

Steven Urvan (together with the other participants in his solicitation, the “Urvan Group” or “we”), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ: POWW) (“AMMO”...

DD : 40.93 (-1.35%)
WRAP : 2.50 (-8.76%)
CLAR : 3.38 (-3.15%)
SPA : 18.51 (+0.11%)
AYRO : 7.08 (+23.13%)
SWBI : 10.83 (-1.55%)
OLN : 22.18 (-0.63%)
VSTO : 44.63 (+0.54%)
PTPI : 0.0127 (+0.79%)
POWW : 1.9800 (unch)
HD : 359.65 (+0.61%)
MDA.TO : 25.32 (-1.52%)
Petros Pharmaceuticals Responds to Fraudulent Press Release

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today...

PTPI : 0.0127 (+0.79%)

Business Summary

Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use...

See More

Key Turning Points

3rd Resistance Point 0.0191
2nd Resistance Point 0.0175
1st Resistance Point 0.0150
Last Price 0.0127
1st Support Level 0.0109
2nd Support Level 0.0093
3rd Support Level 0.0068

See More

52-Week High 16.2500
Fibonacci 61.8% 10.0464
Fibonacci 50% 8.1301
Fibonacci 38.2% 6.2138
Last Price 0.0127
52-Week Low 0.0102

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar